The Genetic Architecture of Multiple Myeloma

Multiple myeloma is a malignant proliferation of monoclonal plasma cells leading to clinical features that include hypercalcaemia, renal dysfunction, anaemia, and bone disease (frequently referred to by the acronym CRAB) which represent evidence of end organ failure. Recent evidence has revealed myeloma to be a highly heterogeneous disease composed of multiple molecularly-defined subtypes each with varying clinicopathological features and disease outcomes. The major division within myeloma is between hyperdiploid and nonhyperdiploid subtypes. In this division, hyperdiploid myeloma is characterised by trisomies of certain odd numbered chromosomes, namely, 3, 5, 7, 9, 11, 15, 19, and 21 whereas nonhyperdiploid myeloma is characterised by translocations of the immunoglobulin heavy chain alleles at chromosome 14q32 with various partner chromosomes, the most important of which being 4, 6, 11, 16, and 20. Hyperdiploid and nonhyperdiploid changes appear to represent early or even initiating mutagenic events that are subsequently followed by secondary aberrations including copy number abnormalities, additional translocations, mutations, and epigenetic modifications which lead to plasma cell immortalisation and disease progression. The following review provides a comprehensive coverage of the genetic and epigenetic events contributing to the initiation and progression of multiple myeloma and where possible these abnormalities have been linked to disease prognosis.

[1]  J. Rivas,et al.  Deregulation of microRNA expression in the different genetic subtypes of multiple myeloma and correlation with gene expression profiling , 2010, Leukemia.

[2]  P. Gómez-Puertas,et al.  Determination of Key Residues for Catalysis and RNA Cleavage Specificity , 2009, The Journal of Biological Chemistry.

[3]  Andrew Lees,et al.  Cloning of the Gene Containing Mutations that Cause PARK8-Linked Parkinson's Disease , 2004, Neuron.

[4]  D. Gerhard,et al.  Dysregulation of cyclin D1 by translocation into an IgH gamma switch region in two multiple myeloma cell lines. , 1996, Blood.

[5]  G. Morgan,et al.  Mapping of Chromosome 1p Deletions in Myeloma Identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as Being Genes in Regions Associated with Adverse Survival , 2011, Clinical Cancer Research.

[6]  M. Smyth,et al.  Critical Role for Tumor Necrosis Factor–related Apoptosis-inducing Ligand in Immune Surveillance Against Tumor Development , 2002, The Journal of experimental medicine.

[7]  Kenneth C. Anderson,et al.  Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group , 2003, British journal of haematology.

[8]  G. Morgan,et al.  MMSET deregulation affects cell cycle progression and adhesion regulons in t(4;14) myeloma plasma cells , 2009, Haematologica.

[9]  P. Moreau,et al.  Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Z. Herceg,et al.  Epigenetic drivers and genetic passengers on the road to cancer. , 2008, Mutation research.

[11]  R. Hayes,et al.  Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. , 2009, Blood.

[12]  G. Morgan,et al.  XBP1s levels are implicated in the biology and outcome of myeloma mediating different clinical outcomes to thalidomide-based treatments. , 2010, Blood.

[13]  I. Puzanov,et al.  Vemurafenib (RG67204, PLX4032): a potent, selective BRAF kinase inhibitor. , 2012, Future oncology.

[14]  H. Asaoku,et al.  Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas , 1988, Nature.

[15]  B. Klein,et al.  Interleukin-6 in human multiple myeloma. , 1995, Blood.

[16]  P. L. Bergsagel,et al.  Genetic aberrations and survival in plasma cell leukemia , 2008, Leukemia.

[17]  H. Avet-Loiseau,et al.  Chromosome 13 abnormalities in multiple myeloma are mostly monosomy 13 , 2000, British journal of haematology.

[18]  W. Kraus,et al.  New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs , 2012, Nature Reviews Molecular Cell Biology.

[19]  B. Barlogie,et al.  Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management , 2010, Leukemia.

[20]  Rafael Fonseca,et al.  Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling. , 2007, Cancer research.

[21]  John Calvin Reed,et al.  BCL-X expression in multiple myeloma: possible indicator of chemoresistance. , 1998, Cancer research.

[22]  Allan S. Brett,et al.  Prevalence of Monoclonal Gammopathy of Undetermined Significance , 2006 .

[23]  N. Munshi,et al.  Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment. , 2006, Cancer research.

[24]  D. Hose,et al.  Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation , 2010, Haematologica.

[25]  B. Barlogie,et al.  Cytogenetic findings in 200 patients with multiple myeloma. , 1995, Cancer genetics and cytogenetics.

[26]  M. Fiegl,et al.  Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy. , 1998, Blood.

[27]  R. Bataille,et al.  Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors. , 2001, Blood.

[28]  Cheng Li,et al.  Prognostic significance of copy-number alterations in multiple myeloma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  T. Libermann,et al.  Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. , 1996, Blood.

[30]  G. Morgan,et al.  A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value. , 2010, Blood.

[31]  M. Moran,et al.  A small-molecule inhibitor of D-cyclin transactivation displays preclinical efficacy in myeloma and leukemia via phosphoinositide 3-kinase pathway. , 2011, Blood.

[32]  R. Bataille,et al.  Monosomy 13 is associated with the transition of monoclonal gammopathy of undetermined significance to multiple myeloma. Intergroupe Francophone du Myélome. , 1999, Blood.

[33]  S. Lonial,et al.  Bortezomib-induced "BRCAness" sensitizes multiple myeloma cells to PARP inhibitors. , 2010, Blood.

[34]  B. Barlogie,et al.  International Myeloma Working Group molecular classification of multiple myeloma: spotlight review , 2009, Leukemia.

[35]  R. Kyle,et al.  The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia, or amyloidosis. , 1985, Blood.

[36]  Thomas Meitinger,et al.  Mutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic Pathology , 2004, Neuron.

[37]  D. Tollervey,et al.  The exosome subunit Rrp44 plays a direct role in RNA substrate recognition. , 2007, Molecular cell.

[38]  Huey-Jen Lin,et al.  Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development. , 2010, Cancer cell.

[39]  P. L. Bergsagel,et al.  The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts. , 1998, Blood.

[40]  T. Therneau,et al.  Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. , 2007, The New England journal of medicine.

[41]  Liewei Wang,et al.  MMSET regulates histone H4K20 methylation and 53BP1 accumulation at DNA damage sites , 2010, Nature.

[42]  D. Reece,et al.  Impact of genomic aberrations including chromosome 1 abnormalities on the outcome of patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone , 2010, Leukemia & lymphoma.

[43]  John Crowley,et al.  The molecular classification of multiple myeloma. , 2006, Blood.

[44]  G. Morgan,et al.  Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myeloma , 2006, Leukemia.

[45]  G. Roodman.  Targeting the bone microenvironment in multiple myeloma , 2010, Journal of Bone and Mineral Metabolism.

[46]  N. Munshi,et al.  Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. , 2007, Blood.

[47]  Thomas W. Mühleisen,et al.  Common variation at 3p22.1 and 7p15.3 influences multiple myeloma risk , 2011, Nature Genetics.

[48]  G. Morgan,et al.  Age has a profound effect on the incidence and significance of chromosome abnormalities in myeloma , 2005, Leukemia.

[49]  G. Morgan,et al.  Deletions of CDKN2C in Multiple Myeloma: Biological and Clinical Implications , 2008, Clinical Cancer Research.

[50]  J. Crowley,et al.  International staging system for multiple myeloma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  P. Tassone,et al.  Integrin β7-mediated regulation of multiple myeloma cell adhesion, migration, and invasion. , 2011, Blood.

[52]  H. Abken,et al.  Regression of metastatic melanoma in a patient by antibody targeting of cancer stem cells. , 2012 .

[53]  A. Tefferi,et al.  BRAF mutations in hairy-cell leukemia [2] , 2011 .

[54]  Fiona M Ross,et al.  Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma. , 2011, Blood.

[55]  Govind Bhagat,et al.  BLIMP1 is a tumor suppressor gene frequently disrupted in activated B cell-like diffuse large B cell lymphoma. , 2010, Cancer cell.

[56]  J. Turkson,et al.  Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. , 1999, Immunity.

[57]  P. L. Bergsagel,et al.  Molecular pathogenesis and a consequent classification of multiple myeloma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  M. Rue,et al.  Clinical and biologic implications of recurrent genomic aberrations in myeloma. , 2003, Blood.

[59]  L. Bruhn,et al.  Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. , 2007, Cancer cell.

[60]  C. Croce,et al.  MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis , 2008, Proceedings of the National Academy of Sciences.

[61]  L. Hendershot,et al.  CHOP-independent apoptosis and pathway-selective induction of the UPR in developing plasma cells. , 2010, Molecular immunology.

[62]  P. L. Bergsagel,et al.  Multiple myeloma: evolving genetic events and host interactions , 2002, Nature Reviews Cancer.

[63]  O. Stephens,et al.  Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma. , 2008, Blood.

[64]  Z. Estrov,et al.  Atiprimod blocks STAT3 phosphorylation and induces apoptosis in multiple myeloma cells , 2005, British Journal of Cancer.

[65]  R. Bataille,et al.  Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. , 2007, Blood.

[66]  B. Barlogie,et al.  Plasma cell karyotype in multiple myeloma. , 1988, Blood.

[67]  P. Loehrer,et al.  International Staging System for Multiple Myeloma , 2006 .

[68]  R. Sitia,et al.  Managing and exploiting stress in the antibody factory , 2007, FEBS letters.

[69]  P. L. Bergsagel,et al.  Molecular pathogenesis of multiple myeloma and its premalignant precursor. , 2012, The Journal of clinical investigation.

[70]  Terry M Therneau,et al.  A long-term study of prognosis in monoclonal gammopathy of undetermined significance. , 2002, The New England journal of medicine.

[71]  P. L. Bergsagel,et al.  Characterization of MYC translocations in multiple myeloma cell lines. , 2008, Journal of the National Cancer Institute. Monographs.

[72]  S. Pileri,et al.  BRAF mutations in hairy-cell leukemia. , 2011, The New England journal of medicine.

[73]  Tsung-Cheng Chang,et al.  Widespread microRNA repression by Myc contributes to tumorigenesis , 2008, Nature Genetics.

[74]  C. Rubin,et al.  Formation of a hyperdiploid karyotype in childhood acute lymphoblastic leukemia. , 1992, Blood.

[75]  L. Staudt,et al.  Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. , 2007, Cancer cell.

[76]  M. Beksac,et al.  Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study. , 2013, Blood.

[77]  G. Morgan,et al.  The t(14;20) is a poor prognostic factor in myeloma but is associated with long-term stable disease in monoclonal gammopathies of undetermined significance , 2010, Haematologica.

[78]  H. Avet-Loiseau,et al.  8p21.3 deletion suggesting a probable role of TRAIL-R1 and TRAIL-R2 as candidate tumor suppressor genes in the pathogenesis of multiple myeloma , 2013, Medical Oncology.

[79]  L. Staudt,et al.  IRF4 addiction in multiple myeloma , 2008, Nature.

[80]  Gabriele Sales,et al.  Identification of microRNA expression patterns and definition of a microRNA/mRNA regulatory network in distinct molecular groups of multiple myeloma. , 2009, Blood.

[81]  K. Anderson,et al.  Genetic variegation of clonal architecture and propagating cells in leukaemia , 2011, Nature.

[82]  D. Reece,et al.  The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant , 2004, British journal of haematology.

[83]  F. Zhan,et al.  The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. , 2003, The New England journal of medicine.

[84]  K. Tarte,et al.  JAK2 tyrosine kinase inhibitor tyrphostin AG490 downregulates the mitogen‐activated protein kinase (MAPK) and signal transducer and activator of transcription (STAT) pathways and induces apoptosis in myeloma cells , 2000, British journal of haematology.

[85]  B. Barlogie,et al.  Secondary genomic rearrangements involving immunoglobulin or MYC loci show similar prevalences in hyperdiploid and nonhyperdiploid myeloma tumors , 2008, Genes, chromosomes & cancer.

[86]  Terry M Therneau,et al.  Prevalence of monoclonal gammopathy of undetermined significance. , 2006, The New England journal of medicine.

[87]  Dixie L. Mager,et al.  MiRNAs, epigenetics, and cancer , 2008, Mammalian Genome.

[88]  M. Gordon.  Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma , 2009 .

[89]  B. Barlogie,et al.  Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma. , 2001, Blood.

[90]  Yongsheng Huang,et al.  A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. , 2006, Blood.

[91]  G. Morgan,et al.  A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial , 2011, Leukemia.

[92]  Z. Estrov,et al.  Nuclear factor–κB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis , 2004 .

[93]  P. L. Bergsagel,et al.  Bone lesions in molecular subtypes of multiple myeloma. , 2004, The New England journal of medicine.

[94]  J. Doroshow,et al.  Advances in using PARP inhibitors to treat cancer , 2012, BMC Medicine.

[95]  G. Morgan,et al.  High expression levels of the mammalian target of rapamycin inhibitor DEPTOR are predictive of response to thalidomide in myeloma , 2010, Leukemia & lymphoma.

[96]  L. Staudt,et al.  The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells. , 2011, Blood.

[97]  T. Soussi,et al.  Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma , 2010, Haematologica.

[98]  G. Morgan,et al.  A Gene Expression–Based Predictor for Myeloma Patients at High Risk of Developing Bone Disease on Bisphosphonate Treatment , 2011, Clinical Cancer Research.

[99]  F. Zhan,et al.  A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains an IGH/MMSET fusion transcript. , 2003, Blood.

[100]  T. Jensen,et al.  The exosome: a multipurpose RNA-decay machine. , 2008, Trends in biochemical sciences.

[101]  Laurence Lodé,et al.  Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myélome. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[102]  G. Morgan,et al.  The genetic architecture of multiple myeloma , 2012, Nature Reviews Cancer.

[103]  J. Miguel,et al.  Prognostic value of numerical chromosome aberrations in multiple myeloma: A FISH analysis of 15 different chromosomes. , 1998, Blood.

[104]  G. Morgan,et al.  First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial , 2010, The Lancet.

[105]  Trevor J Pugh,et al.  Initial genome sequencing and analysis of multiple myeloma , 2011, Nature.

[106]  P. L. Bergsagel,et al.  AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies. , 2008, Cancer cell.

[107]  O. Decaux,et al.  Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor? , 2011, Blood.

[108]  H. Johnsen,et al.  Possible roles for activating RAS mutations in the MGUS to MM transition and in the intramedullary to extramedullary transition in some plasma cell tumors. , 2005, Blood.

[109]  B. Séraphin,et al.  A single subunit, Dis3, is essentially responsible for yeast exosome core activity , 2007, Nature Structural &Molecular Biology.

[110]  Y. Gazitt.  TRAIL is a potent inducer of apoptosis in myeloma cells derived from multiple myeloma patients and is not cytotoxic to hematopoietic stem cells , 1999, Leukemia.

[111]  C. Bastard,et al.  Chromosomal analysis in multiple myeloma: cytogenetic evidence of two different diseases , 1998, Leukemia.

[112]  F. Zhan,et al.  Over-expression of CKS1B activates both MEK/ERK and JAK/STAT3 signaling pathways and promotes myeloma cell drug-resistance , 2010, Oncotarget.

[113]  Tony Reiman,et al.  In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression. , 2003, Blood.

[114]  G. Ahmann,et al.  Prognostic factors for hyperdiploid-myeloma: effects of chromosome 13 deletions and IgH translocations , 2006, Leukemia.

[115]  M. Penichet,et al.  TRAF6 activation in multiple myeloma: a potential therapeutic target. , 2012, Clinical lymphoma, myeloma & leukemia.

[116]  B. Barlogie,et al.  Methylation and expression of the p16INK4A tumor suppressor gene in multiple myeloma. , 2007, Blood.

[117]  P. L. Bergsagel,et al.  Early genetic events provide the basis for a clinical classification of multiple myeloma. , 2005, Hematology. American Society of Hematology. Education Program.

[118]  B. Barlogie,et al.  Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. , 1995, Blood.

[119]  S. Ely,et al.  A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6. , 2006, Cancer research.

[120]  Tutut Herawan,et al.  Computational and mathematical methods in medicine. , 2006, Computational and mathematical methods in medicine.

[121]  G. Morgan,et al.  Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myeloma. , 2007, Blood.

[122]  C. Bastard,et al.  Hypodiploidy is a major prognostic factor in multiple myeloma. , 2001, Blood.

[123]  G. Gahrton,et al.  The prognostic significance of 8p21 deletion in multiple myeloma , 2008, British journal of haematology.

[124]  R. Fonseca,et al.  Deletions of chromosome 13 in multiple myeloma identified by interphase FISH usually denote large deletions of the q arm or monosomy , 2001, Leukemia.

[125]  B. Aggarwal,et al.  Curcumin (Diferuloylmethane) Inhibits Constitutive and IL-6-Inducible STAT3 Phosphorylation in Human Multiple Myeloma Cells 1 , 2003, The Journal of Immunology.

[126]  J. Carpten,et al.  Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. , 2012, Blood.

[127]  R. Fonseca,et al.  Clinical and biological significance of RAS mutations in multiple myeloma , 2008, Leukemia.

[128]  Bart Barlogie,et al.  Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. , 2005, Blood.

[129]  C. Harley,et al.  Telomerase Inhibition Targets Clonogenic Multiple Myeloma Cells through Telomere Length-Dependent and Independent Mechanisms , 2010, PloS one.

[130]  A. Protopopov,et al.  The Differentiation and Stress Response Factor XBP-1 Drives Multiple Myeloma Pathogenesis , 2007, Cancer cell.

[131]  Neal N. Iwakoshi,et al.  Plasma cell differentiation requires the transcription factor XBP-1 , 2001, Nature.

[132]  David R Williams,et al.  High-risk myeloma is associated with global elevation of miRNAs and overexpression of EIF2C2/AGO2 , 2010, Proceedings of the National Academy of Sciences.

[133]  S. Bicciato,et al.  Molecular classification of multiple myeloma: a distinct transcriptional profile characterizes patients expressing CCND1 and negative for 14q32 translocations. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[134]  J. Wilusz,et al.  RNA recognition by 3'-to-5' exonucleases: the substrate perspective. , 2008, Biochimica et biophysica acta.

[135]  J. Shaughnessy.  Amplification and overexpression of CKS1B at chromosome band 1q21 is associated with reduced levels of p27 Kip1 and an aggressive clinical course in multiple myeloma , 2005, Hematology.

[136]  K. Hemminki,et al.  Familial risks and temporal incidence trends of multiple myeloma. , 2006, European journal of cancer.

[137]  H. Johnsen,et al.  Identification of translocation products but not K-RAS mutations in memory B cells from patients with multiple myeloma , 2010, Haematologica.

[138]  B. Bonavida,et al.  Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin's lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[139]  Kenneth C. Anderson,et al.  Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets , 2007, Nature Reviews Cancer.

[140]  L. Staudt,et al.  Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma. , 2004, Cancer cell.